Affinia Therapeutics

Remix Therapeutics is a clinical-stage biotechnology company based in Watertown, MA, focused on developing small molecule therapies that modulate RNA processing to address the underlying drivers of diseases, particularly in the oncology space. Founded in 2020, the company aims to transform patients' lives by creating new therapeutic options for conditions with high unmet medical needs. With a proprietary drug discovery platform, Remix Therapeutics harnesses cellular machinery to control RNA processing and identify druggable targets. The company's commitment to scientific integrity and urgency is driven by the belief that patients are counting on innovative solutions to improve their outcomes. Generated from the website

Rana Therapeutics is a Cambridge-based company that focuses on disease areas, science technology, partnering, sustainable business, and careers. They offer a range of products and services for patients, healthcare professionals, and investors, and are committed to making a positive impact in the healthcare industry. With a strong emphasis on research and development, Rana Therapeutics aims to provide innovative solutions for various diseases. They prioritize accountability and transparency, as evidenced by their financial results, stock information, and press releases. As a reputable company, Rana Therapeutics is dedicated to improving patient outcomes and fostering partnerships within the healthcare community.Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.